CAR‑T Cell Ther­a­py in Lym­phomas, Acute Lym­phoblas­tic Leukemia, and Mul­ti­ple Myeloma

CAR‑T cell ther­a­py rep­re­sents one of the most impor­tant exam­ples of adop­tive immunother­a­py suc­cess­ful­ly trans­lat­ed into mod­ern oncol­o­gy prac­tice. The treat­ment is based on the col­lec­tion of a patient’s own T lym­pho­cytes, their genet­ic mod­i­fi­ca­tion to express a chimeric anti­gen recep­tor, and sub­se­quent rein­fu­sion after lym­phode­plet­ing chemother­a­py. This approach enables T cells to rec­og­nize select­ed tumor-asso­ci­at­ed anti­gens and ini­ti­ate a cyto­tox­ic immune response inde­pen­dent­ly of con­ven­tion­al HLA-medi­at­ed anti­gen presentation.

To date, the most estab­lished clin­i­cal role of CAR‑T ther­a­py has been in B‑cell malig­nan­cies and mul­ti­ple myelo­ma. In dif­fuse large B‑cell lym­phoma, CAR‑T cells have become a stan­dard ther­a­peu­tic option for select­ed patients with relapsed or refrac­to­ry dis­ease, includ­ing those treat­ed in the sec­ond-line set­ting after ear­ly relapse or pri­ma­ry refrac­tori­ness to immunochemother­a­py. In man­tle cell lym­phoma, CAR‑T ther­a­py is used in heav­i­ly pre­treat­ed patients, par­tic­u­lar­ly after fail­ure of Bru­ton tyro­sine kinase inhibitors. In B‑cell acute lym­phoblas­tic leukemia, CAR‑T cells have enabled deep and durable remis­sions in patients with relapsed or refrac­to­ry dis­ease, includ­ing pedi­atric and young adult pop­u­la­tions. In mul­ti­ple myelo­ma, BCMA-direct­ed CAR‑T con­structs have shown high response rates in patients pre­vi­ous­ly exposed to mul­ti­ple lines of therapy.

Despite its trans­for­ma­tive effi­ca­cy, CAR‑T cell ther­a­py is asso­ci­at­ed with a dis­tinct tox­i­c­i­ty pro­file, includ­ing cytokine release syn­drome, immune effec­tor cell-asso­ci­at­ed neu­ro­tox­i­c­i­ty syn­drome, pro­longed cytope­nias, infec­tions, and hypogam­ma­glob­u­line­mia. There­fore, care­ful patient selec­tion, time­ly refer­ral, spe­cial­ized cen­ter expe­ri­ence, and mul­ti­dis­ci­pli­nary col­lab­o­ra­tion are essen­tial for safe and effec­tive treat­ment delivery.

The devel­op­ment of CAR‑T ther­a­py illus­trates how rapid­ly the bound­aries between basic sci­ence, cel­lu­lar engi­neer­ing, trans­la­tion­al research, and clin­i­cal oncol­o­gy are evolv­ing. It also high­lights the need for inte­grat­ed coöper­a­tion between clin­i­cians, mol­e­c­u­lar diag­nos­tics experts, immu­nol­o­gists, cell ther­a­py lab­o­ra­to­ries, and health­care sys­tems to make advanced cel­lu­lar ther­a­pies broad­ly acces­si­ble to patients.

CAR‑T cell ther­a­py rep­re­sents one of the most impor­tant exam­ples of adop­tive immunother­a­py suc­cess­ful­ly trans­lat­ed into mod­ern oncol­o­gy prac­tice. The treat­ment is based on the col­lec­tion of a patient’s own T lym­pho­cytes, their genet­ic mod­i­fi­ca­tion to express a chimeric anti­gen recep­tor, and sub­se­quent rein­fu­sion after lym­phode­plet­ing chemother­a­py. This approach enables T cells to rec­og­nize select­ed tumor-asso­ci­at­ed anti­gens and ini­ti­ate a cyto­tox­ic immune response inde­pen­dent­ly of con­ven­tion­al HLA-medi­at­ed anti­gen presentation.

To date, the most estab­lished clin­i­cal role of CAR‑T ther­a­py has been in B‑cell malig­nan­cies and mul­ti­ple myelo­ma. In dif­fuse large B‑cell lym­phoma, CAR‑T cells have become a stan­dard ther­a­peu­tic option for select­ed patients with relapsed or refrac­to­ry dis­ease, includ­ing those treat­ed in the sec­ond-line set­ting after ear­ly relapse or pri­ma­ry refrac­tori­ness to immunochemother­a­py. In man­tle cell lym­phoma, CAR‑T ther­a­py is used in heav­i­ly pre­treat­ed patients, par­tic­u­lar­ly after fail­ure of Bru­ton tyro­sine kinase inhibitors. In B‑cell acute lym­phoblas­tic leukemia, CAR‑T cells have enabled deep and durable remis­sions in patients with relapsed or refrac­to­ry dis­ease, includ­ing pedi­atric and young adult pop­u­la­tions. In mul­ti­ple myelo­ma, BCMA-direct­ed CAR‑T con­structs have shown high response rates in patients pre­vi­ous­ly exposed to mul­ti­ple lines of therapy.

Despite its trans­for­ma­tive effi­ca­cy, CAR‑T cell ther­a­py is asso­ci­at­ed with a dis­tinct tox­i­c­i­ty pro­file, includ­ing cytokine release syn­drome, immune effec­tor cell-asso­ci­at­ed neu­ro­tox­i­c­i­ty syn­drome, pro­longed cytope­nias, infec­tions, and hypogam­ma­glob­u­line­mia. There­fore, care­ful patient selec­tion, time­ly refer­ral, spe­cial­ized cen­ter expe­ri­ence, and mul­ti­dis­ci­pli­nary col­lab­o­ra­tion are essen­tial for safe and effec­tive treat­ment delivery.

The devel­op­ment of CAR‑T ther­a­py illus­trates how rapid­ly the bound­aries between basic sci­ence, cel­lu­lar engi­neer­ing, trans­la­tion­al research, and clin­i­cal oncol­o­gy are evolv­ing. It also high­lights the need for inte­grat­ed coöper­a­tion between clin­i­cians, mol­e­c­u­lar diag­nos­tics experts, immu­nol­o­gists, cell ther­a­py lab­o­ra­to­ries, and health­care sys­tems to make advanced cel­lu­lar ther­a­pies broad­ly acces­si­ble to patients.

CAR-T Cell Therapy in Lymphomas, Acute Lymphoblastic Leukemia, and Multiple Myeloma
CAR-T Cell Therapy in Lymphomas, Acute Lymphoblastic Leukemia, and Multiple Myeloma
CAR-T Cell Therapy in Lymphomas, Acute Lymphoblastic Leukemia, and Multiple Myeloma

Woj­ciech Szlasa

Physi­cian at the Hema­tol­ogy Depart­ment of DCOPIH, assis­tant at the Depart­ment of Mol­e­c­u­lar and Cel­lu­lar Biol­o­gy at the Wro­claw Med­ical Uni­ver­si­ty (UMW) in Wrocław. Con­ducts research on CAR‑T cell ther­a­py, bis­pe­cif­ic anti­bod­ies, and the com­bi­na­tion of radio­ther­a­py with immunother­a­py in hema­to­log­i­cal malignancies. 

He gained expe­ri­ence in cell ther­a­py dur­ing an intern­ship in Würzburg — one of Europe’s lead­ing CAR‑T cen­ters — as well as through col­lab­o­ra­tion with the Uni­ver­sité de Lor­raine (Nan­cy), focus­ing on mol­e­c­u­lar mod­el­ing and gene elec­tro­trans­fer across can­cer cell mem­branes. He inte­grates exper­i­men­tal work with com­pu­ta­tion­al mod­el­ing and the trans­la­tion of results into clin­i­cal hemato-oncology.

Wojciech Szlasa
Woj­ciech Szlasa, DCOPIH, POLAND

Read the Abstracts from Our Invit­ed Speakers

Can­cer Biology

Can­cer Neuroscience

Can­cer Therapy

PORT for Busi­ness — Com­pa­ny Session